All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1700+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Business Development

OS Therapies acquires Ayala Pharmaceuticals' cancer immunotherapy programs, including Phase 2 lung and Phase 1 prostate cancer assets
Bioengineered bacteria, lung cancer, prostate cancer - Read more

Stryker sells its US spinal implants business to Viscogliosi Brothers
Medical device, spinal implants - Read more

THE GOOD
Clinical Trials

Cullinan Therapeutics and Taiho Pharmaceutical's zipalertinib (targeting EGFR exon 20 mutations) delivers a Ph2b win in previously treated non-small-cell lung cancer
Small molecule, lung cancer - Read more

Regulus Therapeutics touts positive Ph1b data for farabursen (miR-17 inhibitor) in polycystic kidney disease
Oligonucleotide, polycystic kidney disease - Read more

Kashiv Biosciences' KSHB002 (abatacept biosimilar, Bristol Myers Squibb) hits Ph1 endpoints in rheumatoid arthritis
Fusion protein, rheumatoid arthritis - Read more

Gameto advances to Ph3 trial with stem cell-based ovary-in-a-dish technology to improve in vitro fertilization
In-vitro fertilization, fertility, stem cells - Read more

PRESENTED BY YOU?
Get the attention of 1700+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

⬇️ More Good News ⬇️

THE GOOD
Earnings & Finances

Drug companies show restraint in 2024 price increases, with median 4% rise across 930 products, down from historical highs
Drug pricing, price increases - Read more

THE GOOD
Fundraises

8VC targets a $1B Fund VI, with funding focus including life science and healthcare
Venture capital, biotech investing, life science investing - Read more

Curie.Bio $340M additional funding, funding biotech start-ups with both capital and “expert assistance”
Venture capital, biotech investing, biotech accelerator - Read more

Forbion €164.5M ($178.5M) Fund I close, European VC firm launches biotech fund for sustainable food and agriculture solutions
Venture capital, biotech investing, bioag investing - Read more

Imvax $29M financing round from existing investors, developing tumor-derived immunotherapy for glioblastoma treatment trials
Antisense oligonucleotide, glioblastoma, brain cancer, tumor-derived immunotherapy, drug-device combo - Read more

Delfina $17M Series A, maternal health analytics platform expanding nationwide and developing AI tech
Maternal health, analytic platform, AI - Read more

Clarametyx Biosciences undisclosed amount Series A extension, develops therapies for biofilm infections and CF-related treatments
Monoclonal antibody, cystic fibrosis-related infections, recurrent bacterial infection - Read more

Tevogen Bio $10M grant funding, develops T cell therapeutics for cancer and viral infection treatments
Cell therapy, cancer, viral infection, allogeneic T cell - Read more

THE GOOD
Marketing

Bipartisan senators reintroduce bill requiring drug companies to display prescription medication prices in consumer advertisements
Drug advertising, drug pricing - Read more

THE GOOD
Mergers & Acquisition

Lonza announces plans leverage M&A to expand biologics capacity and diversify offerings (following recent revenue declines and planned divestitures)
CDMO, contract manufacturing, biologics manufacturing - Read more [Paywall]

HOPE Therapeutics and NRx Pharmaceuticals secure $27M funding deal to acquire and expand psychiatric clinics for depression and PTSD treatment nationwide.
Interventional psychiatry, depression, post-traumatic stress disorder - Read more

Cormica acquires Focus Laboratories, expanding its US medical testing presence with facilities in Pennsylvania and Florida.
Microbiological testing, rapid microbiology - Read more

Zimmer Biomet to acquire foot and ankle orthopedics company Paragon 28 for $1.1 billion, with additional performance-based payments possible.
Medical device, orthopedics - Read more

THE GOOD
Partnerships

Acellera Therapeutics, Psivant Therapeutics partner to combine AI and modelling platforms for accelerated drug discovery
Small molecule, drug discovery, AI, computational modelling - Read more

TME Pharma, aimed analytics partner to accelerate drug discovery & development using AI and “without the need for time and resource-intensive laboratory testing“
Small molecule, drug development, drug discovery, AI - Read more

ImmunityBio, BeiGene (soon to be BeOne Medicines) partnering on Phase 3 trial combining Anktiva (IL-15 receptor stimulator) and tislelizumab (targeting PD-1) for non-small cell lung cancer treatment
Fusion protein, lung cancer, monoclonal antibody, clinical collaboration - Read more

Fengate Private Equity, eMAX Health partner to advance pharmaceutical commercialization through tech-enabled research platforms
Platform investment, research platform, commercialization, market access - Read more

Knight Therapeutics and Helsinn expand partnership for Onicit (5-HT3 receptor antagonist) distribution across Latin America, including Mexico and Brazil.
Commercialization partnership, nausea associated with chemotherapy, nausea associated with surgery - Read more

THE GOOD
Politics & Policy

Trump administration pledges more transparency in Medicare drug price negotiations, following Biden's 15-drug negotiation plan
Medicare, Inflation Reduction Act, drug pricing, drug pricing negotiations - Read more

Trump administration quickly reverses federal grant freeze after causing nationwide confusion and reciving multiple legal challenges
Grant funding, federal grant freeze - Read more [Paywall]

THE GOOD
Research

Study finds hormone therapies such as suvorexant and melanin-concentrating hormone can improve sleep in ALS mice, offering potential treatment for sleep disruptions in ALS patients
Amyotrophic lateral sclerosis - Read more

Tulane researchers discover genetic signature that predicts bacteria's potential to develop antibiotic resistance, aiding future treatment strategies
Antibiotic resistance, precision medicine - Read more

Unsurprisingly, decentralized clinical trials achieve better diversity, enrolling more Asian, Native American, and female participants than traditional trials
Decentralized clinical trial, clinical trial equity - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Clinical Trials

CARGO Therapeutics discontinues Ph2 trial of firi-cel (CD19 targeting) in large B-cell lymphoma due to safety concerns and limited durability
Cell therapy, lymphoma, cancer, autologous CAR-T - Read more

THE BAD
Earnings & Finances

Teva shares drop 15% after disappointing Q4 results and weak 2025 outlook, with quarterly revenue falling 5% to $4.2B.
Big pharma earnings - Read more

THE BAD
Layoffs

I-Mab cuts 27% of staff during restructuring, focusing on CLDN18.2/4-1BB program and expecting $3M annual savings.
Bispecific antibody, gastric cancer, monoclonal antibody - Read more

CARGO Therapeutics slashes workforce in half after discontinuing lymphoma cell therapy clinical asset
Cell therapy, lymphoma, cancer, autologous CAR-T - Read more

Biotech R&D software company Benchling reduces workforce by 10% in latest round of tech industry layoffs.
Research & development, software, AI - Read more

THE BAD
Market Reports

Contract research organizations face continued slow demand from Big Pharma through 2025 according to William Blair analysts
CRO, contract research - Read more

THE BAD
Politics & Policy

RFK Jr. faces Senate scrutiny over vaccine views during HHS confirmation hearing, attempts to moderate previous controversial statements
Department of Health & Human Services, political appointee, anti-vaccine, conspiracy theories - Read more

THE BAD
Strategic Plans

23andMe seeks strategic options, including potential sale, as cash reserves drop to $79.4M, raising concerns about business continuity
Genetic sequencing, genetic testing, consumer health - Read more

THE UGLY
Lawsuits

Federal health agencies oppose Johnson & Johnson's $10 billion talc settlement, citing potential impact on government reimbursement rights
Talc, ovarian cancer - Read more

THE UGLY
Politics & Policy

Trump signs executive order banning federal support for gender-affirming care for Americans under 19 years old
Gender-affirming care - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here